| Autor: |
Ping Yang, Qing‐qing Cai, Wei Zhang, Shuo‐zi Liu, Hui Liu, Xiu‐hua Sun, Yu‐jun Dong, Xiu‐bin Xiao, Jing‐wen Wang, Zhen‐ling Li, Wen‐rong Huang, Li‐hong Li, Hui‐zheng Bao, Wei Yang, Ya‐lan Wang, Shu‐ye Wang, Juan He, Xiao‐ling Li, Ai‐chun Liu, Hong‐mei Jing |
| Rok vydání: |
2022 |
| Předmět: |
|
| Popis: |
In this study, we aimed to investigate treatment options and the prognosis of patients with mantle cell lymphoma in China. 805 patients diagnosed with MCL between April 1999 and December 2019 at 19 comprehensive hospitals in China were included in this retrospective analysis. The median age of the cohort was 60.0 years with a male-to-female ratio of 3.36:1. 5-year progression free survival (PFS) and overall survival (OS) rates were 30.9% and 65.0% respectively. High-intermediate/high risk group according to MIPI-c, without high-dose cytarabine, lack of Auto-SCT as consolidation and maintenance treatment and SD/PD in initial treatment remained statistically relevant to poor PFS on multivariate analysis (MVA), and ki67 ≥ 50%, B symtoms, high-intermediate/high risk group according to MIPI-c ,without high-dose cytarabine ,lack of maintenance treatment ,SD/PD in initial treatment and relapse/refractory state were independently associated with poorer OS on MVA. First-line high dose cytarabine exposure, auto-SCT as consolidation therapy obtained survival benefits in Chinese population. and our study further confirmed the value of maintenance treatment and explored the application of new drug treatment and bendamustine in R/R MCL patients. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
